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Inflammatory mechanisms may be involved in atherosclerotic plaque rupture. By using 
a novel histology-based method to quantify plaque instability here, we assess whether 
lectin pathway (LP) of complement activation, a major inflammation arm, could represent 
an index of plaque instability. Plaques from 42 consecutive patients undergoing carotid 
endarterectomy were stained with hematoxylin-eosin and the lipid core, cholesterol
clefts, hemorrhagic content, thickness of tunica media, and intima, including or not
infiltration of cellular debris and cholesterol, were determined. The presence of ficolin-1, 
-2, and -3 and mannose-binding lectin (MBL), LP initiators, was assessed in the plaques 
by immunofluorescence and in plasma by ELISA. LP activation was assessed in plasma 
by functional in vitro assays. Patients presenting low stenosis (≤75%) had higher hem-
orrhagic content than those with high stenosis (>75%), indicating increased erosion.
Increased hemorrhagic content and tunica media thickness, as well as decreased lipid 
core and infiltrated content were associated with vulnerable plaques and therefore used 
to establish a plaque vulnerability score that allowed to classify patients according to 
plaque vulnerability. Ficolins and MBL were found both in plaques’ necrotic core and 
tunica media. Patients with vulnerable plaques showed decreased plasma levels and
intraplaque deposition of ficolin-2. Symptomatic patients experiencing a transient isch-
emic attack had lower plasma levels of ficolin-1. We show that the LP initiators are
present within the plaques and their circulating levels change in atherosclerotic patients. 
In particular, we show that decreased ficolin-2 levels are associated with rupture-prone 
vulnerable plaques, indicating its potential use as marker for cardiovascular risk assess-
ment in atherosclerotic patients.
 
 
 
 
 
Keywords: cardiovascular diseases, atherosclerosis, complement system proteins, ficolin-2, vulnerable plaques
Abbreviations: HS, high stenosis (>75%); LP, lectin pathway of complement activation; LS, low stenosis (≤75%); MBL, 
mannose-binding lectin.
Table 1 | Patients’ details.
Total patients = 37 %
Age mean ± SD 73.03 ± 7.42
Gender (M/F) 31/6 84/16
Symptomatic (Y/N) 11/26 30/70
Stenosis (symptomatic) 70% 3 (2) 8 (67)
75% 12 (2) 32 (17)
80% 11 (3) 30 (27)
85% 4 (1) 11(25)
90% 7 (3) 19 (43)
Therapy with statins 33 89
Therapy with antiaggregants 35 95
No therapy 1 0.4
Smoking
 Current 6 16
 Former 21 57
 Never 10 27
Diabetes mellitus 16 43
Obesity 9 24
Hypertension 32 86
Dyslipidemia 34 92
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highlighTs
 – Initiators of the lectin pathway of complement activation are 
expressed in atherosclerotic plaques.
 – The activation of the lectin pathway is increased in vulnerable 
atherosclerotic plaques.
 – Low Ficolin-2 plasma levels are associated with vulnerable 
atherosclerotic plaques.
 – Ficolin-1 plasma levels are lower in symptomatic (vs. non-
symptomatic) patients experiencing a transient ischemic 
attack.
inTrODUcTiOn
Acute cardiovascular events, such as myocardial infarction and 
ischemic stroke, are associated with progression and rupture of 
unstable atherosclerotic plaques. Key to advance prevention of 
neurologic complications and to improve therapy is the early 
detection of rupture-prone atherosclerotic carotid plaques. 
Patients with stenosis above 70% may be eligible for surgical 
intervention, e.g., endoarterectomy (1). The degree of carotid 
stenosis is the only valid criterion currently used in clinical 
decision-making to assess the severity of atherosclerotic disease 
(2). However, stenosis alone is insufficient to reliably predict 
plaque instability. Unstable, or vulnerable, plaques may erode 
causing thromboembolic complications (3) and increased risk 
of transient ischemic attack and stroke recurrence (4, 5). Several 
morphologic studies using non-invasive imaging techniques have 
been published (6, 7); however, a clear-cut clinical definition of 
vulnerable plaques is not available; therefore, a meaningful sur-
rogate of lesion instability detecting vulnerable plaques before 
symptomatology is needed.
Atherosclerosis depends on processes such as the oxidative 
modification of lipoproteins in the arterial walls, represent-
ing danger stressors that activate several components of the 
inflammatory response (8–10), including the complement sys-
tem (11). The lectin pathway (LP) is a complement activation 
pathway showing a critical role in thrombosis (12). Moreover, 
the LP has pathogenetic functions in acute brain injuries 
such as ischemia or traumatic injury in experimental models 
(13–16) and in humans (13, 16–20), pathological conditions 
showing vascular impairment. The LP is activated by the 
initiator molecules mannose-binding lectin (MBL), ficolins 
(ficolin-1 or M-ficolin, ficolin-2 or L-ficolin, and ficolin-3 or 
H-ficolin), and collectin-11 (21–23). A few studies reported 
MBL involvement in atherosclerosis, though results are con-
trasting, supporting either an anti-atherogenic (24–28) or a 
pro-atherogenic (29–31) role. A few data are available on the 
LP involvement in plaque vulnerability (32), with still open 
questions.
In this study, we propose a histology-based approach that 
provides a quantitative assessment of plaque vulnerability. We 
selected four morphological parameters associated with plaque 
instability to set a vulnerability score. Finally, we investigated the 
association of LP initiators and activation with plaque vulner-
ability as indicated by the vulnerability score.
MaTerials anD MeThODs
Patients
Plaques were obtained from 42 consecutive patients undergoing 
carotid endarterectomy. Patients were symptomatic (experienc-
ing a transient ischemic attack (TIA)) and asymptomatic refer-
ring to department of Vascular Surgery at A. Gemelli Hospital 
during 2013–2015. Clinical data, obtained as part of standard 
patient care, and samples were retrospectively examined with the 
approval of the local ethical committee Board (Comitato Etico 
della Fondazione Policlinico Universitario A. Gemelli, reference 
number: 26089/16). Degree (%) of stenosis was assessed by 
echocolordoppler. Patients were stratified by 70, 75, 80, 85, and 
90% stenosis, according to the ECST criteria (33) and guidelines 
of Italian Society of Vascular and Endovascular Surgery (34). 
Only patients with stenosis ≥70% were subjected to surgery and 
therefore included in this study (34). Patients were excluded from 
surgery and therefore from this study when the operation risks 
were considered too high.
Patients’ details, including therapies and comorbidities, are 
reported in Table 1. None of the patients had any autoimmune 
disease.
sample Processing
Immediately after surgery specimens were snap-frozen. The 
plaques were examined macroscopically to identify the site of the 
maximal plaque thickening and then transversely dissected into 
two segments along the longitudinal axis. The plaque segment 
showing the largest plaque burden as determined by visual assess-
ment was defined as the zero (0) segment (35). The rationale is 
that the segment of a plaque with the largest plaque burden is 
generally, where the largest lipid core and the more extensive 
inflammation are present. The 0 segment was the reference seg-
ment and the adjacent 1-mm-thick segments at both sides were 
called ±1, ±2, … The plaque region cut and used for histological 
analysis ranged from segments −1 to +1, being defined as the 
FigUre 1 | histological analysis of plaques. (a) Lipid core area by 
manual outline tracing. (b) Cholesterol clefts area by software-based 
segmentation (black selection). (c) Hemorrhagic content by software-based 
segmentation (red selection). (D) Thickness of tunica media (heavy lines) and 
total thickness of tunica including infiltration of cellular debris and cholesterol 
(heavy and thin lines). The ratio between total and tunica media lengths 
corresponds to infiltrated content. Areas expressed in μm2 and normalized for 
total plaque area (μm2). Scale bar = 1 mm.
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segments with the greatest plaque burden. Plaque segment cut-
ting was performed on dry ice. Segments embedded in optimal 
cutting temperature medium were then transferred to a cryostate 
and cut in 20 μm-thick slices. Slices were laid on a gelatinized glass 
for subsequent histological stainings. Before stainings, sections 
were thawed by 5 min washing with 0.05M triphosphate buffer 
saline (TBS) at room temperature (RT) and then post-fixated by 
15 min incubation with 4% paraformaldheyde.
Blood samples were obtained one day after surgery. Clotting 
and complement activation were prevented by collecting samples 
in 10  mM of ethylenediaminetetraacetic acid (EDTA). Plasma 
was processed at 2,000  g for 15  min at 4°C and stored −80°C 
before analysis.
histological analysis
Hematoxyline and eosin (H&E) staining was performed accord-
ing to standard protocols. H&E stained slices were acquired at 
20× using a Nikon Eclipse Ni-E virtual stage microscope so to 
have complete stitching of the whole plaques at high resolution 
(1 pixel = 0.345 μm). A digital repository of stained plaques was 
created and used for subsequent quantifications. As a first evalu-
ation, an investigator blinded to patients’ clinical data identified 
plaques with signs of rupture according to the classification 
proposed by Virmani et  al. (36). For quantifications, images 
were scaled to microns. The area of intra-intimal lipid-rich core 
with hemorrhage and cholesterol clefts was calculated. Lipid 
core area was outlined on the plaque by manual operator selec-
tion (Figure 1A). In the lipid core area, cholesterol clefts were 
identified by gray scale thresholding and selected (Figure  1B). 
Hemorrhagic area was identified by digital color thresholding 
based on RGB pixel values (Figure 1C). Hemorrhagic content, 
lipid core, and cholesterol cleft areas were calculated as μm2 and 
expressed as percentage of total plaque area. Plaque thickness was 
measured manually along the traces outlined in Figure 1D. Total 
tunica thickness was measured at the thickest point at the border 
of the vascular lumen and the media layer, excluding adventitial 
cutting artifacts from analysis. The media thickness was meas-
ured from the intimo-medial interface to the external border. The 
intra-intima infiltrated content of cellular debris and cholesterol 
(from here on referred to as “infiltrated content”) was defined 
as the ratio between total tunica thickness and media thickness.
immunofluorescence and confocal 
analysis
After thorough washings with PBS 0.01M, 20-μm coronal sec-
tions were incubated with blocking solution (10% normal goat 
serum, 0.3% Triton X-100) for 1 h at RT and then with primary 
antibodies in the same solution overnight at 4°C. Primary mono-
clonal antibodies used were anti-human MBL (1:50, Abcam, 
USA), anti-human ficolin-3 (1:50, Hycult Biotechnologies, NL), 
and anti-human ficolin-2 and ficolin-1 (both 1:50) (37).
Sections were then incubated with biotinylated secondary 
antibody (1:200, Vector Laboratories) for 1 h at RT and followed by 
fluorescent signal coupling with streptavidine TSA amplification 
kit (fluorescein, Perkin Elmer, USA). Sections were then incu-
bated with True-Black quencher (1:20 in 70% Ethanol, Biotium, 
USA) to quench non-specific fluorescent signal. Appropriate 
negative controls without the primary antibodies were per-
formed. None of the immunofluorescence reactions revealed 
unspecific fluorescent signal in the negative controls (Figure S1 
in Supplementary Material). Immunofluorescence was acquired 
using a scanning sequential mode to avoid bleed-through effects 
by an IX81 microscope equipped with a confocal scan unit FV500 
with three laser lines: Ar–Kr (488 nm), He–Ne red (646 nm), and 
He–Ne green (532 nm, Olympus, JPN), and a UV diode. Three-
dimensional images were acquired over a 10 μm z-axis with a 
0.23 μm step size and processed using Imaris software (Bitplane, 
CH) and Photoshop CS2 (Adobe Systems Europe Ltd.). Exclusion 
images on single focal planes were obtained by Fiji software image 
calculator protocol (“subtract” function).
Functional lP-specific c3 Deposition 
assay
A LP specific C3 deposition ELISA was performed to measure 
residual LP functional activity in patient plasma (38). A Maxisorp 
ELISA plate (NUNC™) was coated with 10 μg/mL mannan to 
test LP activation by MBL (38, 39), or 25 μg/mL acetylated bovine 
serum albumin (acBSA) to test LP activation by ficolins (21, 40) 
diluted in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 
9.6) and incubated overnight at 4°C. Residual protein binding 
sites were saturated by incubating the plate with 1% BSA-TBS 
blocking buffer (0.1% (w/v) BSA in 10  mM Tris–CL, 140  mM 
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NaCl, 1.5  mM NaN3, pH 7.4) overnight at 4°C. The plate was 
then washed with washing buffer (TBS with 0.05% Tween 20 
and 5  mM CaCl2). EDTA-plasma samples were thawed on ice 
and suspended in barbital buffered saline (BBS; 4 mM barbital, 
145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4), to a final 
plasma concentration of 6%. Wells receiving only BBS buffer were 
used as negative controls. Plasma solutions were incubated on 
the coated plate at 37°C for 1 h 30 min (40 μL/well). The plate 
was washed and incubated for 1 h 30 min at RT with a polyclonal 
anti-human C3c antibody (Dako, A0062) diluted 1:5,000 in 
washing buffer. After washing, the plate was incubated with 
an alkaline-phosphatase labeled goat anti-rabbit IgG antibody 
(Sigma A-3812) diluted 1:5,000 in washing buffer for 1 h 30 min 
at RT. Following washing, the assay was developed by adding 
100 μL substrate solution (Sigma Fast p-Nitrophenyl Phosphate 
tablets, Sigma). The absorption at OD405 nm was then measured 
using the Infinite M200 spectrofluorimeter managed by Magellan 
software (Tecan, CH).
lP initiator Quantification
Ficolin-1, ficolin-2, ficolin-3, and MBL in plasma were analyzed 
after plasma incubation on acBSA or mannan-coated plates 
prepared according to the procedure reported in the previ-
ous paragraph. The plates were incubated for 1 h 30min at RT 
with mouse polyclonal anti-human MBL (HM2061, Hycult 
Biotechnologies, The Netherlands), anti-human ficolin-1 (41), 
anti-human ficolin-2 (37), and anti-human ficolin-3 (HM2089, 
Hycult Biotechnologies, The Netherlands), all diluted 1:100 in 
washing buffer. After washing, the plates were incubated with 
an HRP labeled goat anti-mouse IgG antibody (Santacruz, CA, 
USA) diluted 1:1,000 in washing buffer for 1  h 30  min at RT. 
Following washing, the assay was developed by adding 100 μL 
substrate solution TMB (TMB Substrate Kit; code 34021; Thermo 
Scientific, MA, USA; 1:1 with H2O2 solution). The reaction was 
stopped by adding 100 μL H2SO4 2M, and absorption at OD450 
nm was measured as above reported. The specificity of ficolin 
binding to acBSA was shown by the lack of binding to BSA or to 
uncoated plates (Figure S2 in Supplementary Material).
immunofluorescence Quantification
Ficolin-2 stained sections were acquired at 10× (pixel size of 
0.646  μm) with an Olympus BX-61 Virtual Stage microscope 
so to have complete stitching of the whole plaque for the two 
color channels (DAPI and ficolin-2). Analysis was done using Fiji 
software. Briefly, the region of interest was delineated within the 
necrotic area referring to the corresponding H&E image. After 
separation of the color channels, the ficolin-2 signal channel was 
normalized by imposing a 0 gray level value to background noise. 
To this purpose, three background areas were calculated for their 
mean gray value and this mean value subtracted to the whole 
image. Ficolin-2 signal was then calculated as integrated density 
within the region of interest.
blinding and statistical analysis
All histological and plasma quantifications were performed by 
investigators blinded to patients’ clinical information. Patients 
were stratified by the degree of carotid stenosis (≤75 vs. >75%) 
to assess whether the relationships between plaque components 
were modified by severity of atherosclerosis. Fisher’s exact test 
was used to define the association between hemorrhagic content 
and plaque rupture and whether patients with low stenosis 
(≤75%) had higher hemorrhagic plaques. Column analysis after 
patient stratification was done by Mann–Whitney test in case 
of non-normal distribution of data or unpaired t-test in case 
of normal distribution. Normal distribution was assessed by 
Kolmogorov–Smirnov test. A “vulnerability score” was obtained 
stratifying plaque components (hemorrhagic content, lipid core 
area, media thickness, and infiltrated content) into four groups 
according to their quartiles. The total score ranged from 4 (stable 
plaque) to 16 (vulnerable plaque). Correlation analysis was per-
formed by computing a Pearson r or Spearman r depending on 
data distribution. The Forest plot was obtained using the odds 
ratios calculated stratifying patients for high plaque vulner-
ability (defined as a score ≥12) and high protein levels (defined 
as optical density ≥ median of each protein tested in the ELISA 
assay). Correlations of ficolin-2 integrated density were done by 
computing the Spearman r since ficolin-2 values did not have a 
normal distribution (Kolmogorov–Smirnov test for normality). 
Statistical analysis was performed using standard software pack-
ages GraphPad Prism (GraphPad Software Inc., USA, version 
6.0). All tests were two-sided and p values lower than 0.05 were 
considered statistically significant. Details on the statistical analy-
sis applied for each experiment are reported in figure legends.
resUlTs
Patients’ Details and stratification 
strategy
Of the 42 patients undergoing endoarterectomy, 5 were excluded 
due to excessive plaque fragility hampering cryostat sectioning 
(4) or to unsatisfactory staining (1). We therefore analyzed a 
total of 37 patients (Table 1). The mean age of the patients was 
73.03 ± 7.42. In line with the prevalence of atherosclerosis in the 
general population (42, 43), men outnumbered women (31 vs. 
6). All patients but one received either statins or antiaggregants; 
therefore, we did not correct data for treatment. The cohort was 
homogeneous for conventional risk factors, with majority of 
either current or former smokers (73%), having hypertension 
(86%), and dyslipidemia (92%).
Only 30% (11 out of 37) of patients were symptomatic, e.g., 
had single or recurrent transient ischemic attacks, making them 
eligible for urgent surgery. Clinically, patients were classified 
according to stenosis degree (%) in five ranks: 70, 75, 80, 85, 
and 90%.
Seventeen out of 37 patients showed ruptured plaques accord-
ing to the morphological evaluation proposed by Virmani et al. 
(36) and depicted in Figure 2A. Plaque rupture was associated 
with a high hemorrhagic content (>1.98%, threshold defined 
on the hemorrhagic content median value; Fisher’s exact test, 
p = 0.022, Figure 2B). We therefore used the measure of hem-
orrhagic content as a quantitative indicator of plaque rupture. 
Contingency analysis revealed that patients with less stenosis 
(70–75%) were more likely to have hemorrhagic plaques than 
FigUre 2 | Prevalence of ruptured and hemorrhagic plaques. (a) Plaques were evaluated for the presence of rupture sites by an investigator blinded to the 
clinical and histological data. Scale bar = 500 μm. (b) Ruptured plaques were associated with high hemorrhagic content. (c) Plaques from LS patients 
(stenosis ≤ 75%) had higher hemorrhagic content indicating their vulnerability. Threshold between high and low hemorrhagic content was set at cohort’s median 
value (1.98%). Fisher’s exact test, p = 0.022 for (b) and p = 0.006 for (c).
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patients with higher stenosis (80–85–90%, Fisher’s exact test, 
p = 0.006, Figure 2C). This suggests that in the cohort analyzed, 
patients with ≤75% stenosis had more ulcerated, rupture-prone 
plaques (44). On the contrary, stenosis was not associated with 
the occurrence of symptoms (Fisher’s exact test, p = 1.000, data 
not shown). The observation that in the analyzed cohort, patients 
with low degree of stenosis had ulcerated, rupture-prone plaques 
was used as a criteria to stratify patients according to the pres-
ence of vulnerable plaques (low stenosis, LS) vs. those with stable 
plaques (high stenosis, HS). To test the hypothesis that lower 
degree of stenosis may be due to the erosion of vulnerable plaques 
and to define a histology-based evaluation of plaque vulnerability, 
we next quantified parameters of plaque morphology.
histological Quantification of 
Morphological characteristics associated 
with Plaque Vulnerability
Atherosclerotic plaques were quantified for the following mor-
phological characteristics, representing parameters associated 
with plaque instability (45): hemorrhagic content, cholesterol 
clefts, lipid core area, media thickness, total tunica thickness, and 
infiltrated content (Figure 3).
Plaques from LS patients had higher hemorrhagic content than 
those from HS patients (mean ± SD: 3.69 ± 2.17 vs. 1.67 ± 1.48% of 
plaque area, p = 0.003). These two groups did not differ for either 
cholesterol cleft area or tunica thickness (media + intima thick-
ness). Patients with LS had smaller lipid core area (31.04 ± 15.72 
vs. 42.60 ± 12.12% of plaque area, p = 0.016) and less infiltrated 
content (3.57 ± 1.87 vs. 5.77 ± 3.73 total tunica/media, p = 0.048) 
than HS patients. In line with these data, LS patients had thicker 
tunica media (530.1 ±  266.0 vs. 372.5 ±  156.6 μm, p =  0.031) 
since either less infiltration exerts less compression on this area or 
lamina becomes thicker and flaky, therefore favoring instability.
These data indicate that, in the cohort of patients analyzed, 
eroded plaques (associated to LS and increased hemorrhagic 
content) can be histologically defined based on smaller infiltra-
tion and increased tunica media thickness.
lP initiator Presence in the 
atherosclerotic Plaques
We next sought to detect the presence of LP initiators 
within the plaques. We performed immunofluorescence for 
ficolin-1, ficolin-2, ficolin-3, and MBL, initiators of the LP (46). 
Ficolin-1 (Figures  4A,A′), ficolin-2 (Figures  4B,B′), and fico-
lin-3 (Figures 4C,C′) were present both in lipid core and tunica 
media, as further confirmed by the exclusion images showing 
ficolin selective signal in tunica. Ficolins were found in plaques 
with either low or high hemorrhagic content. MBL was present 
in lipid core and tunica media in plaques with high hemorrhagic 
content (>median 1.98%, Figures  5A,A′), while did not show 
any presence in plaques with low hemorrhagic content (<1.98%, 
Figures 5B,B′).
Plaque Vulnerability score
The presence of ficolin-1, -2, and -3 and MBL in the atheroscle-
rotic plaques suggested that the LP is activated and involved in 
atherosclerotic events, therefore making it a candidate marker of 
pathology. To correlate LP activity to plaque vulnerability, a com-
prehensive vulnerability score was obtained based on quartile 
FigUre 3 | Quantitative histological analysis of plaque morphology after patient stratification for stenosis. LS patients had plaques with higher 
hemorrhagic content and media thickness, smaller lipid core area, and lower infiltrated content than HS. Thus LS plaques show erosion. Data presented as dot 
plots, line at mean ± SD. Mann–Whitney test for hemorrhagic content, unpaired t-test for others. LS, low stenosis; HS, high stenosis.
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distribution of all four risk parameters (Figure 3): hemorrhagic 
content, lipid core area, media thickness, and infiltrated content. 
The total score ranged between 4 (stable) and 16 (vulnerable, 
Figures 6A,A′). Table 2 summarizes the histological information 
relative to each degree of stenosis.
Measurement of residual lP activity and 
Proteins in Plasma samples
A functional ELISA was used to measure residual LP activity 
in plasma based on C3 deposition on plates coated with the 
best-affinity ligands for MBL (mannan) or ficolins (acBSA) (38), 
as indicated by the data shown in Figure S3 in Supplementary 
Material. Vulnerability score significantly correlated with LP acti-
vation by MBL (C3 deposition on mannan, Spearman’s correlation 
test, p = 0.015), but not by ficolins (Figure 6B). In line with this, 
the LP activation by MBL was associated with vulnerable plaques 
(Figure  6C) showing lower lipid core, increased tunica media 
thickness, and lower infiltrated content (Figure 7A). In contrast, 
ficolin-2 was decreased in plasma from patients with vulnerable 
plaques, indicating its use (consumption) in pathway activation 
and possibly driving plaque instability (Figure  6C). However, 
ficolin-2 plasma level changes did not affect the functional assay 
of C3 deposition on acBSA (Figures 6C and 7B).
It is likely that an acute cardiovascular event (such as TIA, 
these patient symptom) affects the circulating levels of the LP 
proteins (17, 19). This implies that a central event may affect LP 
levels independently from the atherosclerotic process. In order 
to have a clear view of the events related to atherosclerosis, 
we have analyzed our data excluding the symptomatic patients 
(Figure 6D; Figure S4 in Supplementary Material). The asso-
ciations between LP protein plasma levels and plaque vulner-
ability were confirmed analyzing only the non-symptomatic 
patients.
FigUre 4 | Ficolin 1, 2, and 3 presence in plaques. Microphotograms of the lipid core (left) and tunica media (right). (a,a′) Ficolin-1 (red) was in both lipid core 
and tunica media. To exclude the collagen non-selective fluorescent signal, we obtained an exclusion image showing only the ficolin-1 specific signal (green) and 
confirmed ficolin-1 presence in tunica media. (b,b′) Ficolin-2 (red) and (c,c′) Ficolin-3 (red) were also in lipid core and tunica media. Nuclei are blue. Scale 
bars = 20 μm.
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FigUre 5 | Mannose-binding lectin (Mbl) presence in plaques. Microphotograms of the lipid core (left) and tunica media (right). MBL was present in lipid core 
and tunica media in high hemorrhagic [hemorrhagic content >1.98% (a,a′)] but not in low hemorrhagic (b,b′) plaques as further confirmed by the exclusion 
images. Nuclei are blue. Scale bars = 20 μm.
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By analyzing the plasma levels of each LP initiator, stratifying 
patients using the median values of the four histological param-
eters associated with plaque vulnerability—hemorrhagic content, 
lipid core area, media thickness, and infiltrated content—we found 
that MBL and ficolin-3 were higher in plasma from patients with 
increased media thickness (Figures 7C,D). Ficolin-2 decreased 
in plasma of patients with high hemorrhagic content and low 
lipid core area (vulnerable plaques, Figure 7E). Ficolin-1 did not 
change throughout morphological stratifications (Figure  7F). 
These observations are in line with the Forest plot data presented 
in Figure 6C.
When we stratified patients for symptomatology, plasma levels 
of ficolin-1 were lower in symptomatic than in asymptomatic 
patients (Figure 8), and no other differences were found in the 
other LP initiators.
Measurement of Ficolin-2 intraplaque 
Deposition
To define the correlation between LP protein deposition in the 
plaque and plaque vulnerability, we stained the plaques from all 
patients for ficolin-2, the only LP initiator protein changing in 
association with the vulnerability score (see Figures 6C,D). We 
FigUre 6 | activation of the lectin complement pathway in atherosclerotic patients. (a) Scheme for the definition of the vulnerability score obtained on: 
hemorrhagic content, lipid core area, media thickness, and infiltrated content. The score (1–4) for each parameter depends on the value distribution in a given 
quartile, thus the total score ranges from 4 (stable) to 16 (vulnerable). (a′) A total vulnerability score ≥12 was used as a cut-off for high vulnerability when computing 
the odds ratio (OR). (b) LP activation by mannose-binding lectin (MBL), but not by ficolins, positively correlated with the vulnerability score. Spearman’s correlation 
test. (c) Association (OR; 95% confidence interval) between LP and vulnerability score was significant when considering LP activation by MBL and ficolin-2 low 
plasma levels. OR was calculated based on high vulnerability [score ≥12, see (a′)] and high protein plasma levels (≥median OD). (D) Association between LP and 
vulnerability score in non-symptomatic patients only (26/37). In line with the whole cohort data, the association was significant when considering LP activation by 
MBL and ficolin-2 low plasma levels. OR was calculated based on high vulnerability (score ≥12) and high protein plasma levels (≥ median OD). Empty dots indicate 
p < 0.05.
Table 2 | histopathological data related to stenosis degree.
ls hs
(70%) (75%) (80%) (85%) (90%)
Patients number (n = 37) 3 12 11 4 7
Ruptured (n = 17) 1 7 5 2 2
Not ruptured (n = 20) 2 5 6 2 5
Ruptured frequency 33 58 45 50 29
Vulnerability Score
 Hemorrhagic content 3.00 4.00 2.00 3.00 2.00
 Lipid core area 3.00 3.00 2.00 1.00 3.00
 Media thickness 3.00 3.00 2.00 1.00 3.00
 Infiltrated content 4.00 2.50 2.00 1.00 3.00
Total Vulnerability Score 12.00 12.50 8.00 6.00 11.00
LS, low stenosis; HS, high stenosis.
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acquired the whole plaque at high resolution and normalized 
the color channel with the ficolin-2 signal (Figure 9A). Ficolin-2 
intraplaque levels (expressed as integrated density of fluorescent 
pixels in the region of interest), calculated in the necrotic core, 
were inversely correlated with the vulnerability score (Figure 9B), 
similarly to what is observed with circulating ficolin 2. Ficolin-2 
intraplaque levels were directly correlated with the infiltrated 
content (Figure 9C).
DiscUssiOn
This study demonstrates the potential use of LP components as 
markers for cardiovascular risk in atherosclerotic patients show-
ing that: (1) ficolins and MBL, initiators of the LP activation, 
FigUre 7 | activation and initiators of the lectin pathway comparing patients with stable vs. unstable plaques. Patients were stratified using the median 
values of the four histological parameters associated with plaque vulnerability, namely hemorrhagic content, lipid core area, media thickness, and infiltrated content 
(see Figure 3). (a) LP activation driven by mannose-binding lectin (MBL) (C3 deposition on mannan) increased in plasma from patients with low lipid core area, high 
media thickness, and low infiltrated content (unstable plaques). (b) In contrast, LP activation driven by ficolins (C3 deposition on acBSA) did not change between 
stratified patients. (c) MBL was higher in plasma from patients with increased media thickness as well as (D) Ficolin-3. (e) Ficolin-2 decreased in plasma of patients 
with high hemorrhagic content and low lipid core area (vulnerable plaques). (F) Ficolin-1 did not change throughout morphological stratifications. These observations 
are in line with the data presented in Figure 6c. Data are presented as dot plots with line at mean ± SD. In abscissae, median values for each parameter are 
indicated. All measures met normal distribution; therefore, unpaired t-test was performed, significant p values are indicated in graphs.
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FigUre 8 | lP activation and initiator plasma levels after patient stratification on symptomatology. C3 deposition driven by either MBL or ficolins did not 
change depending on symptomatology. Ficolin-1 was significantly lower in plasma of symptomatic patients. Data presented as dot plots with line at mean ± SD. 
Unpaired t-test, significant p values are reported.
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are present within the lipid core and the tunica media of ath-
erosclerotic plaques; (2) plasma levels of ficolin-2 are decreased 
in patients with vulnerable plaques and those of ficolin-1 are 
decreased in symptomatic (vs. non-symptomatic) patients expe-
riencing a transient ischemic attack; (3) the LP activity driven by 
MBL is increased in plasma of patients with vulnerable plaques.
We first defined histological parameters allowing to identify 
vulnerable, rupture-prone plaques within the cohort of analyzed 
patients. We stratified patients in two groups based on the degree 
of stenosis, namely LS and HS, as assessed by preoperative 
echocolordoppler. Plaques from LS patients had increased hem-
orrhagic content, measured by histological quantification, than 
those from HS patients, indicating their unstable nature. In this 
regard, we here report the association of hemorrhagic content 
with signs of rupture within the plaque. Moreover, intraplaque 
neovascularization has been associated with increasing plaque 
inflammation and vulnerability (47, 48), and microvessel-related 
intraplaque hemorrhage has been reported as a predictor fac-
tor for cardiovascular events (49, 50). Intraplaque hemorrhage 
therefore indicates plaques subjected to erosion, which are clas-
sifiable as unstable (45). Eroded plaques are less likely to cause 
vessel narrowing compared to stable, fully developed plaques, 
explaining their prevalence in mildly stenotic patients (51). Along 
with increased intraplaque hemorrhagic content, plaques from 
LS patients have smaller lipid core and lower intimal infiltration. 
Moreover in these rupture-prone plaques the tunica media is 
thicker than that from HS patients, indicating a compensatory 
enlargement of the vessel segment. The complex transition from 
compensatory enlargement to plaque disruption may be a fine 
interaction between progressive intimal disease and evolving 
pathology at the intimomedial interface, including rupture of the 
internal elastic lamina and medial inflammation (51).
We then defined four morphological parameters, namely 
hemorrhagic content, lipid core area, infiltrated content, and 
FigUre 9 | analysis of ficolin-2 intraplaque presence. (a) Ficolin-2 intraplaque presence was calculated by acquiring the whole plaque and obtaining the 
ficolin-2 specific signal after normalization with background subtraction. The region of interest to be analyzed (necrotic area, yellow dashed outline) was delineated 
referring to the corresponding hematoxyline and eosin (H&E) image. Scale bar = 1 mm. (b) Ficolin-2 intraplaque levels were inversely correlated to the vulnerability 
score. (c) On the contrary, ficolin-2 intraplaque levels were directly correlated with the infiltrated content. Spearman correlation test, p values indicated in the figure.
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tunica media thickness that are associated with plaque instability 
in the analyzed cohort of patients. Our findings are partially in 
line with the observation by Takaya et al. who correlated the pres-
ence of intraplaque hemorrhage and the larger maximum wall 
thickness with the risk of cerebrovascular events in 154 asymp-
tomatic patients with definitive 50–70% stenosis, followed-up for 
12 months (52).
We next explored whether histologically defined vulnerable 
plaques were associated with LP activation, aiming at identify-
ing early markers of cardiovascular risk. Evidence supports 
the involvement of the complement system in atherosclerosis. 
When the vascular endothelium is injured, the entrance of lipids 
and active complement fragments, as well as inflammatory cell 
recruitment into the media layer, initiates and intensifies athero-
sclerosis. Of the pathways of complement system activation, the 
classical and alternative have a dual function in atherosclerosis, 
counteracting plaque formation through debris clearance or 
favoring atherogenesis (12). Less is known on the role of the 
LP that may have either an anti-atherogenic (24–27) or a pro-
atherogenic (29–31) and pro-thrombotic function (12).
We analyzed the presence of ficolins and MBL in the athero-
sclerotic plaques. We report the presence of ficolin-1, ficolin-2, 
and ficolin-3 in carotid plaques, specifically within the lipid core 
and in the collagen-rich tunica media. Füst and collaborators (17) 
showed increased ficolin-2 and ficolin-3 serum levels in asymp-
tomatic patients with severe carotid atherosclerosis compared to 
healthy controls or to patients after acute stroke. This suggests 
the involvement of ficolin-2 and ficolin-3 in the atherosclerotic 
process and their rapid consumption after an acute event. We 
show a significant association between low ficolin-2 plasma levels 
and plaque vulnerability, indicative of ficolin-2 use, as the plaque 
becomes vulnerable, a risk factor for an acute cardiovascular 
event. Interestingly, the levels of intraplaque deposited ficolin-2 
are inversely correlated with plaque vulnerability, in line with 
what is observed with circulating ficolin-2. Ficolin-2 deposited in 
the plaque correlates directly with the infiltrated content. Based 
on these observations, as a working hypothesis, we can propose 
that ficolin-2 contributes to plaque erosion, an event that evolves 
over time before the patients’ surgery and that we can observe 
only at a late stage (post-surgery) when intraplaque ficolin-2 is 
lost as a consequence of erosion and circulating ficolin-2 is low 
since it is consumed, i.e., used for the pathway activation. As an 
alternative hypothesis ficolin-2, whose high intraplaque levels 
correlate with low plaque vulnerability, may be protective. In 
this case, ficolin-2 could contribute to debris clearance, in line 
with its function as an opsonin for phagocytosis independent of 
complement activation (53).
Our data originally show ficolin-1 presence within athero-
sclerotic plaques and its significantly lower levels in symptomatic 
patients with transient ischemic attacks compared to non-
symptomatic. This observation is in line with a previous work by 
our group reporting that ficolin-1 is a sensitive prognostic marker 
for stroke patients (19), and further implicates ficolin-1 in acute 
brain injury.
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Reports on MBL in atherosclerosis are contrasting. Patients 
with MBL deficiency have higher risk to develop a cardiovas-
cular event after infection by Chlamydia pneumoniae (25). 
Similarly, patients affected by systemic lupus erythematosus 
and homozygous for MBL variants develop an increased risk 
of arterial thrombosis (26). In a cohort of American Indians, 
variant MBL genotypes have been associated with increased 
risk of coronary artery disease (27). In line with these data, 
Vengen et al. showed that the presence of MBL variant allele may 
increase the risk of myocardial infarction in young individuals 
(32) and Saevarsdottir proposed for MBL an anti-atherogenic 
role (28). On the other hand, high MBL serum levels are associ-
ated with increased risk of coronary artery disease in men (30) 
and in diabetic patients (29). Moreover, patients with normal 
MBL genotype are more likely to experience restenosis after 
endarterectomy (31).
We here show that MBL is selectively present in ulcerated 
(highly hemorrhagic) plaques, maybe due to its limited ability to 
extravasate (15). By the functional in vitro assay measuring C3 
deposition on mannan, our study suggests that MBL-driven LP 
activation is associated with plaque instability. This association 
is further supported by the observation that MBL is present only 
in ulcerated plaques undergoing rupture, therefore extending 
previous work reporting MBL binding to intraplaque cholesterol 
crystals (53), clearly defining that plaque rupture is needed for 
MBL entry. Thus, although alternative interpretations cannot be 
excluded, i.e., that MBL is not consumed due to a lack of involve-
ment in the condition, the overall data may indicate the associa-
tion of MBL with plaque instability. This observation extends the 
concept that MBL in atherosclerosis may have different effects 
depending on time in the disease process and the specific clinical 
setting (29, 32).
In the analyzed cohort, 30% of patients were symptomatic, 
i.e., they experienced a TIA and were eligible for urgent sur-
gery. When we compared symptomatic vs. non-symptomatic 
patients, we could not observe any significant difference in the 
morphological parameter, possibly because the groups were not 
balanced. However, we could detect significantly lower levels 
in circulating ficolin-1 implying that the symptomatology can 
influence LP protein levels. In order to test whether LP protein 
plasma levels may be markers of plaque vulnerability indepen-
dently from symptomatology—their use should ideally help 
decision-making of surgeons in asymptomatic patients—we 
repeated the analysis excluding the 11 symptomatic patients. 
The data obtained are consistent with those obtained on the 
whole cohort indicating that LP protein plasma levels are reliable 
peripheral markers of plaque vulnerability, independently from 
symptomatology.
We cannot exclude that LS patients have still growing rather than 
eroding plaques. However, in the analyzed cohort of patients, LS is 
strongly associated with the presence of high intraplaque hemorrhagic 
content, a clear index of erosion as confirmed by its association with 
plaque rupture. Of note, LS is not associated with symptomatology 
meaning that the observed changes in LP activation (C3 deposition 
on mannan), and in ficolin-2 plasma levels in patients with vulnerable 
plaques are not a mere consequence of a cardiovascular event, but 
rather anticipate clinical symptomatology.
Potential limitations of this study include the small size of patients’ 
cohort that hampered stratifications based on age, sex, or relevant 
comorbidities, all potentially impacting on plaque morphology 
(43, 54). However, the cohort that we analyzed reflects the epidemi-
ology of patients suffering from significant atherosclerosis and eligi-
ble for surgical intervention (54). Data on the LP activation need to 
be extended by recruiting more patients and following them before 
and after surgery. Moreover the use of combinatorial approaches 
including advanced imaging techniques and assessment of other 
plasma complement proteins could add details on the LP role in 
atherosclerosis. This will help address the validity of the LP as a 
marker for future cardiovascular risk in atherosclerotic patients, 
offering solid reasons to select timely treatments in clinical practice.
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